Study of the phenotype of these tumor-affluent CTLs in both models showed that the percentage of polyfunctional T cells (expression or coexpression of IFN-γ, granzyme B [GzmB], TNF-α) (Figure 1, D and F), proliferating T cells (Ki67+) and expression of markers of lymphocyte activation/exhaustion (PD-1/TIM3) (Figure 1, E and G) were also greater in tumors treated with the CDDP-Eri combination, particularly at early time points (day 14). The gene discussed is HAVCR2; the disease is neoplasm.